Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

MannKind stock price, quote, forecast and news

MNKD
US56400P7069
A2DMZL

Price

5.38
Today +/-
+0
Today %
+0 %
P

MannKind stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the MannKind stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the MannKind stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the MannKind stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze MannKind's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

MannKind Stock Price History

DateMannKind Price
8/27/20245.38 undefined
8/26/20245.38 undefined
8/23/20245.37 undefined
8/22/20245.33 undefined
8/21/20245.39 undefined
8/20/20245.25 undefined
8/19/20245.35 undefined
8/16/20245.14 undefined
8/15/20245.19 undefined
8/14/20245.19 undefined
8/13/20245.07 undefined
8/12/20245.19 undefined
8/9/20245.05 undefined
8/8/20245.19 undefined
8/7/20245.01 undefined
8/6/20245.27 undefined
8/5/20245.23 undefined
8/2/20245.34 undefined
8/1/20245.55 undefined
7/31/20245.76 undefined
7/30/20245.76 undefined

MannKind Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into MannKind, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by MannKind from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects MannKind’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of MannKind. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into MannKind’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing MannKind’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on MannKind’s growth potential.

MannKind Revenue, EBIT and net profit per share

DateMannKind RevenueMannKind EBITMannKind Net Income
2029e522.3 M undefined0 undefined0 undefined
2028e474.3 M undefined180.54 M undefined169.44 M undefined
2027e421.32 M undefined164.67 M undefined136.11 M undefined
2026e386.81 M undefined162.8 M undefined83.33 M undefined
2025e330.11 M undefined101.52 M undefined48.15 M undefined
2024e286.09 M undefined62.46 M undefined20.37 M undefined
2023198.96 M undefined15.19 M undefined-11.94 M undefined
202299.8 M undefined-66.7 M undefined-87.4 M undefined
202175.4 M undefined-51.3 M undefined-80.9 M undefined
202065.1 M undefined-37.5 M undefined-57.2 M undefined
201963 M undefined-46.5 M undefined-51.9 M undefined
201827.9 M undefined-81.1 M undefined-87 M undefined
201711.7 M undefined-94.6 M undefined-117.3 M undefined
2016174.8 M undefined62.9 M undefined125.7 M undefined
20150 undefined-138.1 M undefined-368.4 M undefined
20140 undefined-179.6 M undefined-198.4 M undefined
20130 undefined-169.4 M undefined-191.5 M undefined
20120 undefined-140.5 M undefined-169.4 M undefined
2011100,000 undefined-134.2 M undefined-160.8 M undefined
2010100,000 undefined-152.5 M undefined-170.6 M undefined
20090 undefined-209.8 M undefined-220.1 M undefined
20080 undefined-305.8 M undefined-303 M undefined
20070 undefined-307.4 M undefined-293.2 M undefined
2006100,000 undefined-233.7 M undefined-230.5 M undefined
20050 undefined-118.1 M undefined-114.3 M undefined
20040 undefined-77.1 M undefined-95.9 M undefined

MannKind Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
00000000000000000174112763657599198286330386421474522
-------------------93.68145.45133.333.1715.3832.00100.0044.4415.3816.979.0712.5910.13
-----------------71.26-45.4525.9355.5663.0850.6744.4470.71------
0000000000000000-67124-5735413844140000000
-5-25-30-56-66-77-118-233-307-305-209-152-134-140-169-179-13862-94-81-46-37-51-6615621011621641800
-----------------35.63-854.55-300.00-73.02-56.92-68.00-66.677.5821.6830.6141.9738.9537.97-
-5-24-48-207-67-95-114-230-293-303-220-170-160-169-191-198-368125-117-87-51-57-80-87-112048831361690
-380.00100.00331.25-67.6341.7920.00101.7527.393.41-27.39-22.73-5.885.6313.023.6685.86-133.97-193.60-25.64-41.3811.7640.358.75-87.36-281.82140.0072.9263.8624.26-
0.81.32.12.73.75810.21620.321.322.724.436.259.97781.292.1104.2144.1195.6222.6249.2257.1267.01000000
-------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The MannKind Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the MannKind is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
31.155.990.5145.6436.5368.346.532.570.42.761.870.8120.859.122.943.971.249.967204.1170.8295.1
00000000000050.400.32.843.54.2516.814.9
0000000000000030.60000000
0000000000009.702.32.73.64.257.221.828.55
0.91.93.9310.79.663.72.83.14.55.520.217.521.47.83.13.23.33.525.534.85
3257.894.4148.6447.2377.952.536.273.25.866.376.3201.176.677.557.281.960.879.5219.8234.9373.39
72.767.366.576.288.3162.7226.4208.2202.4193184176.6192.148.728.926.925.63025.936.645.188.91
000000000000000000056.627.16
0000000000000000000000
000000000000000000001.21.07
000000000000000000002.41.93
0.10.71.12.31.9221.50.90.70.55.81.210.60.40.233.38.29.72.74
72.86867.678.590.2164.7228.4209.7203.3193.7184.5182.4193.349.729.527.325.83329.2101.460.4101.8
104.8125.8162227.1537.4542.6280.9245.9276.5199.5250.8258.7394.4126.310784.5107.793.8108.7321.2295.3475.2
21.152.20.30.50.7111.11.31.32.93.74.14.34.81.21.92.12.42.52.62.7
0.380.430.590.761.171.441.471.541.591.621.992.262.422.512.552.642.762.82.872.922.962.98
-301.1-367-443-557.3-787.8-1,081-1,384.1-1,604.2-1,774.7-1,935.5-2,104.9-2,296.4-2,494.8-2,863.2-2,737.6-2,854.9-2,940-2,991.9-3,049.1-3,130.1-3,217.5-3,229.41
000000300-3001000000000000000
0000000000000000000000
96.7116.7150.3207383.5364.186.7-59.3-185.4-313.7-110.6-30.7-73.7-350.3-183.6-214.7-175-190.5-180.4-209.4-250.6-246.17
4.21.933.510.735.515.66.53.34.64.63.97.415.63.375.44.85.6711.19.58
1.848.617.834.228.629.418.811.419.620.615.617.36.37.611.91414.617.524.418.224.06
1.92.81.4003.58.43.53.41.15.26206.3171.99.91644.641.246.610.128.430.92
00000000000102.37374.671.352.711.350000
0000000000114.4099.4000004.179.639.57
7.98.71321.344.967.653.428.818.125.3144.8127.8403.4268.492.187.675.365.673.848.567.3104.13
0000111.3111.8142.3277.8444.7487.8217.214852.6139.577.2104.191.2113.9118.2374.7368479.07
0000000000000000000000
0.20.40.10000000013.612.368.9121.4107.6116.4104.897.1107.4110.5138.17
0.20.40.10111.3111.8142.3277.8444.7487.8217.2161.664.9208.4198.6211.7207.6218.7215.3482.1478.5617.24
8.19.113.121.3156.2179.4195.7306.6462.8513.1362289.4468.3476.8290.7299.3282.9284.3289.1530.6545.8721.37
104.8125.8163.4228.3539.7543.5282.4247.3277.4199.4251.4258.7394.6126.5107.184.6107.993.8108.7321.2295.2475.2
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of MannKind provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand MannKind's financial health and stability.

Assets

MannKind's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that MannKind must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of MannKind after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into MannKind's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-48-206-65-75-114-230-293-303-220-170-160-169-191-198-368125-117-86-51-57-80-87-11
1577788121817151414181343202464
00000000000000000000000
40-1171513-5-15-9913213340-1392736-12-9-16-2414
2115177-1164349532722359199265-632616-1843433844
00000144813179131113873139818
00000000000000000000000
-21-48-52-59-101-189-245-271-184-148-123-119-1284-57-78-64-37-88-28-61-8034
-39-34-5-6-17-20-78-82-18-9-60-7-24-10-100-2-4-11-7-42
-39-501-9-94-4838-99-3-11-20-7-24-10-1160-2215-1514-1
0-166-2-77-27116-1715-2300000160-2020-1401240
00000000000000000000000
-210001110301351825312460-64-515-562142860143
7858488417239025506117101671464078506170835122-1
7960821011725012553018919663179145705437361694927021136
3033160000-7-300-5-30-8-2-3-4-10-17-1-5
00000000000000000000000
18-393231-2226348-340236-6359850-61-362523-413657-54168
-60.83-82.82-57.39-66.79-118.4-210.56-323.41-353.74-202.93-158.19-130.7-120.5-136.72-20.01-67.52-79.23-64.78-38.08-91.05-32.91-73.18-88.27-8.35
00000000000000000000000

MannKind stock margins

The MannKind margin analysis displays the gross margin, EBIT margin, as well as the profit margin of MannKind. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for MannKind.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the MannKind's sales revenue. A higher gross margin percentage indicates that the MannKind retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the MannKind's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the MannKind's total revenue generated. When comparing the revenue margin year over year, investors can gauge the MannKind's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the MannKind. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the MannKind's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

MannKind Margin History

MannKind Gross marginMannKind Profit marginMannKind EBIT marginMannKind Profit margin
2029e70.76 %0 %0 %
2028e70.76 %38.06 %35.72 %
2027e70.76 %39.08 %32.3 %
2026e70.76 %42.09 %21.54 %
2025e70.76 %30.75 %14.58 %
2024e70.76 %21.83 %7.12 %
202370.76 %7.64 %-6 %
202244.59 %-66.83 %-87.58 %
202151.06 %-68.04 %-107.29 %
202062.98 %-57.6 %-87.86 %
201955.71 %-73.81 %-82.38 %
201826.52 %-290.68 %-311.83 %
2017-47.01 %-808.55 %-1,002.56 %
201671.34 %35.98 %71.91 %
201570.76 %0 %0 %
201470.76 %0 %0 %
201370.76 %0 %0 %
201270.76 %0 %0 %
201170.76 %-134,200 %-160,800 %
201070.76 %-152,500 %-170,600 %
200970.76 %0 %0 %
200870.76 %0 %0 %
200770.76 %0 %0 %
200670.76 %-233,700 %-230,500 %
200570.76 %0 %0 %
200470.76 %0 %0 %

MannKind Stock Sales Revenue, EBIT, Earnings per Share

The MannKind earnings per share therefore indicates how much revenue MannKind has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue MannKind earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates MannKind's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of MannKind’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating MannKind's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

MannKind Revenue, EBIT and net profit per share

DateMannKind Sales per ShareMannKind EBIT per shareMannKind Earnings per Share
2029e1.92 undefined0 undefined0 undefined
2028e1.74 undefined0 undefined0.62 undefined
2027e1.55 undefined0 undefined0.5 undefined
2026e1.42 undefined0 undefined0.31 undefined
2025e1.21 undefined0 undefined0.18 undefined
2024e1.05 undefined0 undefined0.07 undefined
20230.75 undefined0.06 undefined-0.04 undefined
20220.39 undefined-0.26 undefined-0.34 undefined
20210.3 undefined-0.21 undefined-0.32 undefined
20200.29 undefined-0.17 undefined-0.26 undefined
20190.32 undefined-0.24 undefined-0.27 undefined
20180.19 undefined-0.56 undefined-0.6 undefined
20170.11 undefined-0.91 undefined-1.13 undefined
20161.9 undefined0.68 undefined1.36 undefined
20150 undefined-1.7 undefined-4.54 undefined
20140 undefined-2.33 undefined-2.58 undefined
20130 undefined-2.83 undefined-3.2 undefined
20120 undefined-3.88 undefined-4.68 undefined
20110 undefined-5.5 undefined-6.59 undefined
20100 undefined-6.72 undefined-7.52 undefined
20090 undefined-9.85 undefined-10.33 undefined
20080 undefined-15.06 undefined-14.93 undefined
20070 undefined-19.21 undefined-18.33 undefined
20060.01 undefined-22.91 undefined-22.6 undefined
20050 undefined-14.76 undefined-14.29 undefined
20040 undefined-15.42 undefined-19.18 undefined

MannKind business model

MannKind Corp is a biopharmaceutical company that specializes in the development, production, and marketing of inhalable medications. The company was founded in 1991 by renowned scientist Alfred E. Mann and is headquartered in Westlake Village, California. MannKind Corp's history began with its founding in 1991 and the development of technologies for manufacturing injectable drugs. Over the years, the company has continuously evolved its technologies and now specializes in inhalable medications. MannKind Corp offers a wide portfolio of products in various areas, with the main areas being diabetes, lung and respiratory diseases, and cancer and immunology. The company develops and produces innovative medications and inhalation devices that allow patients to fight their illnesses. In particular, MannKind Corp has achieved significant success in the field of diabetes treatment. The company has developed an inhalable insulin solution that allows patients to quickly and easily inhale insulin. This novel insulin preparation called Afrezza was launched in the U.S. market in 2015 and greatly improves the treatment of both Type 1 and Type 2 diabetes. With Afrezza, MannKind Corp has achieved a milestone in medical history. In addition to Afrezza, MannKind is also working on other promising projects such as an inhalable drug for COPD (chronic obstructive pulmonary disease), an inhalable painkiller, and a cancer medication. The company also operates its own research department to develop new drugs and therapies. To realize its business model, the company utilizes partnerships and joint ventures to successfully bring its products to market. For example, it has formed a partnership with Sanofi, a globally leading biopharmaceutical company, to launch Afrezza in Europe. It has also established a partnership with Receptor Life Sciences Inc. in the U.S. to develop an inhalable cannabinoid medication for neuropathic pain. MannKind Corp is a company with ambitious goals and visions. It has already made significant advancements in development and elevated the treatment of diseases to a higher level. With its innovative products and technologies, the company remains a leading player in the biopharmaceutical industry and contributes to improving people's lives. MannKind is one of the most popular companies on Eulerpool.com.

MannKind SWOT Analysis

Strengths

MannKind Corp operates in the biopharmaceutical industry, specializing in the development and commercialization of novel therapeutic products.

The company possesses advanced scientific and technological expertise, allowing them to innovate and create unique pharmaceutical products.

MannKind has a successful track record in drug development, with a portfolio of approved products that cater to critical medical needs.

Weaknesses

MannKind Corp heavily relies on partnerships for its commercialization and distribution activities, which can limit their control over the entire supply chain.

The company faces financial challenges due to high research and development costs, impacting their ability to generate consistent profits.

MannKind may have limited resources for marketing and promotion compared to larger pharmaceutical competitors.

Opportunities

The increasing demand for innovative pharmaceutical products presents MannKind Corp with opportunities to expand its product portfolio and capture a larger market share.

The company can explore international markets and partnerships to further grow its global presence and increase revenues.

Technological advancements and medical breakthroughs provide MannKind with the chance to develop and introduce new drugs to address unmet medical needs.

Threats

MannKind Corp operates in a highly competitive industry, facing intense competition from well-established pharmaceutical companies.

Regulatory changes and requirements pose a threat to the company's ability to obtain necessary approvals and licenses for its products.

The potential emergence of substitute products or alternative therapies may impact the demand for MannKind's offerings.

MannKind Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

MannKind historical P/E ratio, EBIT, and P/S ratio.

MannKind shares outstanding

The number of shares was MannKind in 2023 — This indicates how many shares 267.014 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue MannKind earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates MannKind's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of MannKind’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating MannKind's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

MannKind Stock splits

In MannKind's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for MannKind.

MannKind latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20240.01 -0.01  (-247.06 %)2024 Q2
3/31/20240.03 0.04  (50.94 %)2024 Q1
12/31/20230 0  (-100 %)2023 Q4
9/30/2023-0.02 0.01  (159.52 %)2023 Q3
6/30/2023-0.04 -0.02  (48.45 %)2023 Q2
3/31/2023-0.05 -0.04  (21.88 %)2023 Q1
12/31/2022-0.06 -0.07  (-10.76 %)2022 Q4
9/30/2022-0.09 -0.06  (31.58 %)2022 Q3
6/30/2022-0.1 -0.11  (-15.18 %)2022 Q2
3/31/2022-0.1 -0.1  (0 %)2022 Q1
1
2
3
4
5
...
8

Eulerpool ESG Scorecard© for the MannKind stock

Eulerpool World ESG Rating (EESG©)

62/ 100

🌱 Environment

35

👫 Social

94

🏛️ Governance

55

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
❌
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
✅

Social

Percentage of female employees42
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting✅
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

MannKind list of shareholders

%
Name
Stocks
Change
Date
7.42 % BlackRock Institutional Trust Company, N.A.20,192,5701,754,70312/31/2023
5.58 % The Vanguard Group, Inc.15,196,069598,89512/31/2023
4.75 % State Street Global Advisors (US)12,940,395723,79412/31/2023
3.98 % Nitorum Capital, L.P.10,831,390360,62112/31/2023
3.30 % Avoro Capital Advisors LLC9,000,000012/31/2023
2.18 % Fidelity Management & Research Company LLC5,940,883-517,74612/31/2023
2.15 % Geode Capital Management, L.L.C.5,842,775327,79512/31/2023
1.10 % D. E. Shaw & Co., L.P.2,988,025-1,219,36612/31/2023
0.92 % Parkman Healthcare Partners LLC2,498,624429,67712/31/2023
0.88 % Goldman Sachs Asset Management, L.P.2,392,684129,97912/31/2023
1
2
3
4
5
...
10

MannKind Executives and Management Board

Dr. Michael Castagna46
MannKind Chief Executive Officer, Director (since 2016)
Compensation 3.91 M
Mr. Steven Binder60
MannKind Chief Financial Officer
Compensation 1.74 M
Dr. David Thomson56
MannKind Executive Vice President, General Counsel, Secretary
Compensation 1.74 M
Dr. Stuart Tross56
MannKind Chief Human Resource Officer, Executive Vice President, Workplace Officer
Compensation 1.61 M
Mr. Sanjay Singh56
MannKind Executive Vice President - Technical Operations
Compensation 853,494
1
2
3

MannKind Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Amphastar Pharmaceuticals Stock
Amphastar Pharmaceuticals
SupplierCustomer0,650,950,14-0,63-0,71-0,07
Cipla Stock
Cipla
SupplierCustomer0,270,850,47-0,35-0,240,71
Model N Stock
Model N
SupplierCustomer-0,400,750,480,790,76-0,09
United Therapeutics Corp Stock
United Therapeutics Corp
SupplierCustomer-0,570,510,520,630,320,86
1

Most common questions regarding MannKind

What values and corporate philosophy does MannKind represent?

MannKind Corp is a pharmaceutical company committed to improving the health and well-being of people. With a strong corporate philosophy focused on innovation and patient-centricity, MannKind Corp prioritizes developing advanced therapies that address unmet medical needs. The company specializes in inhalation therapies for diseases such as diabetes and pulmonary hypertension. MannKind Corp's values revolve around integrity, compassion, and scientific excellence, driving its mission to deliver life-changing treatments. By pushing the boundaries of science and prioritizing patient outcomes, MannKind Corp aims to make a positive impact on global healthcare.

In which countries and regions is MannKind primarily present?

MannKind Corp is primarily present in the United States.

What significant milestones has the company MannKind achieved?

MannKind Corp, a leading pharmaceutical company, has achieved several significant milestones. Firstly, they successfully developed and received approval for their flagship product, Afrezza, an inhalable insulin therapy for diabetes patients. This innovative treatment provides a convenient alternative to traditional injectable insulin. Additionally, MannKind Corp has secured key partnerships with pharmaceutical giants, such as Sanofi, to market and distribute Afrezza globally. The company has also made great strides in the research and development of Technosphere-based therapies, expanding their product portfolio. With their pioneering advancements, MannKind Corp continues to revolutionize diabetes management and strive for enhanced patient outcomes.

What is the history and background of the company MannKind?

MannKind Corp is a pharmaceutical company with a rich history and background. Established in 1991, MannKind Corp primarily focuses on the discovery, development, and commercialization of therapeutic products for patients with various medical conditions. With its headquarters in Westlake Village, California, MannKind Corp has made notable contributions to the pharmaceutical industry. It is best known for its groundbreaking development of Afrezza®, an inhaled insulin used in the treatment of diabetes. MannKind Corp remains committed to advancing medical innovation and improving the lives of patients worldwide through its cutting-edge research and development efforts.

Who are the main competitors of MannKind in the market?

Some of the main competitors of MannKind Corp in the market include Novo Nordisk, Eli Lilly and Company, and Sanofi. These companies also specialize in the development and commercialization of pharmaceutical products. However, MannKind Corp differentiates itself through its proprietary Technosphere® platform and its focus on delivering inhalable therapeutics.

In which industries is MannKind primarily active?

MannKind Corp is primarily active in the biotechnology and pharmaceutical industries.

What is the business model of MannKind?

MannKind Corp is a biopharmaceutical company with a unique business model. The company focuses on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. MannKind Corp is known for its technosphere-based inhalation technology, which allows for the delivery of therapeutic molecules through inhalation. This technology has been utilized in the development of their flagship product, Afrezza, an inhaled insulin for diabetes management. By leveraging innovative inhalation technology, MannKind Corp aims to provide effective and convenient treatment options for patients suffering from various diseases.

What is the P/E ratio of MannKind 2024?

The MannKind P/E ratio is 70.53.

What is the P/S ratio of MannKind 2024?

The MannKind P/S ratio is 5.02.

What is the AlleAktien quality score of MannKind?

The AlleAktien quality score for MannKind is 2/10.

What is the revenue of MannKind 2024?

The expected MannKind revenue is 286.09 M USD.

How high is the profit of MannKind 2024?

The expected MannKind profit is 20.37 M USD.

What is the business model of MannKind

The MannKind Corporation is a biopharmaceutical company based in the USA. The company specializes in the development and marketing of therapeutics for various diseases, particularly respiratory diseases. MannKind's business model is based on innovative technologies that help improve the effectiveness and safety of respiratory disease treatment. The company particularly offers the drug Afrezza, which was developed using the technology of fine moisture particles (Technosphere). The principle of action is that instead of traditional injections, insulin is administered directly to the lungs through inhalation and absorbed into the bloodstream from there. This allows for rapid action and dispensing of insulin without the need for needles. MannKind's main focus is currently on the approval and marketing of Afrezza. The drug is intended to provide an alternative to insulin injections for patients with type 1 and type 2 diabetes mellitus. MannKind acts as a licensor and also collaborates with the pharmaceutical giant Sanofi. Sanofi is allowed to introduce the medication into European and global markets. In addition to Afrezza, MannKind is also active in the development of treatment options for other respiratory diseases such as asthma. The company is working on developing further technologies to make the treatment of these diseases more effective and safer. In addition to their core competence in the field of respiratory diseases, MannKind also invests in the development of products based on their proprietary technologies. Through various research projects and partnerships with other companies, MannKind seeks to apply their technologies in other areas as well. It can be assumed that MannKind has a high interest in protecting their technologies through intellectual property. Patents and licenses are intended to secure the knowledge behind them and protect the investment in the research of future medications. Overall, the MannKind Corporation seems to be a company with great potential. Their business model is based on innovative technologies for the treatment of respiratory diseases and they position themselves as licensors and partners. Another focus is on the development of products based on their technologies. If Afrezza is successfully marketed, MannKind could become an important player in the market, benefiting from their intellectual property and technologies.

What is the MannKind dividend?

MannKind pays a dividend of 0 USD distributed over payouts per year.

How often does MannKind pay dividends?

The dividend cannot currently be calculated for MannKind or the company does not pay out a dividend.

What is the MannKind ISIN?

The ISIN of MannKind is US56400P7069.

What is the MannKind WKN?

The WKN of MannKind is A2DMZL.

What is the MannKind ticker?

The ticker of MannKind is MNKD.

How much dividend does MannKind pay?

Over the past 12 months, MannKind paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, MannKind is expected to pay a dividend of 0 USD.

What is the dividend yield of MannKind?

The current dividend yield of MannKind is .

When does MannKind pay dividends?

MannKind pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of MannKind?

MannKind paid dividends every year for the past 0 years.

What is the dividend of MannKind?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is MannKind located?

MannKind is assigned to the 'Health' sector.

Wann musste ich die Aktien von MannKind kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of MannKind from 8/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/28/2024.

When did MannKind pay the last dividend?

The last dividend was paid out on 8/28/2024.

What was the dividend of MannKind in the year 2023?

In the year 2023, MannKind distributed 0 USD as dividends.

In which currency does MannKind pay out the dividend?

The dividends of MannKind are distributed in USD.

All fundamentals about MannKind

Our stock analysis for MannKind Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of MannKind Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.